HACKENSACK, N.J., January 17, 2017 – With more than 20 existing cancer care delivery locations throughout New Jersey, Maryland and Washington, D.C., Regional Cancer Care Associates, or RCCA, started 2017 by adding six Connecticut-based cancer specialists to the network. RCCA’s northward expansion to Connecticut is in keeping with the network’s mission of providing patients with access to comprehensive, patient-centric treatment in their own communities.
The new Connecticut-based division of RCCA has practice locations in both Hartford and Manchester, and the cancer specialists’ hospital affiliations include Saint Francis Hospital and Medical Center in Hartford, Manchester Memorial Hospital in Manchester, and Rockville General Hospital in Vernon, CT. The six cancer specialists who are joining RCCA in the Connecticut locations are Charanjeev S. Kapoor, MD; Joseph F. McLaughlin, MD; Mohammad Pazooki, MD; Michael A. Reale, MD, PhD; Joel S. Silver, MD; and Joseph G. Sinning, MD.
Terrill Jordan, President and CEO of RCCA, said, “We are honored that some of the most highly regarded oncologists and hematologists practicing in Connecticut have chosen to join RCCA due to our shared commitment to community-based care, maintaining an unwavering focus on the patient, and the primacy of the physician in clinical decision-making.” Mr. Jordan added, “In an increasingly complex healthcare environment marked by both unparalleled opportunities to help cancer patients and unprecedented operational and financial challenges for physicians, RCCA exists to help both patient and physician thrive.”
Mr. Jordan noted that in October 2015, RCCA expanded from New Jersey to Maryland and Washington, DC, which represented one of the first instances of a fully unified cancer care organization expanding across state lines. He added, “RCCA’s track record of providing innovative care is well known, and was recognized by the Centers for Medicare and Medicaid Services’ recent decision to have RCCA participate in the Oncology Care Model, a new care-delivery and reimbursement model formulated to enhance the efficiency and effectiveness of care for people receiving chemotherapy. All of us at RCCA look forward to collaborating with our new Connecticut-based colleagues in further extending that record of excellent patient care provided in the community setting.”
One of the Connecticut-based cancer specialists joining RCCA, Michael A. Reale, MD, PhD, said, “At a time when the evolution of healthcare delivery in the US necessitates that physicians affiliate with larger entities, it was important to me to join a physician-owned and –operated network that reflected my own philosophy of providing comprehensive, compassionate, and personalized care in a setting that supports a strong physician-patient relationship.” Dr. Reale went on to say, “Additionally, my colleagues and I are involved in a number of clinical research projects, and RCCA’s extensive clinical trials program will enable us to continue that vital work and to offer our patients access to a variety of studies and cutting-edge therapies.”
More than 100 oncology physicians and nurse clinicians practice with RCCA in the oncology network’s 20+ care centers throughout New Jersey, Connecticut, Pennsylvania, Maryland and the Washington, DC, area.
The physicians, nurses and other health care professionals of RCCA provide care to roughly 24,500 new cancer patients and 245,000 established patients each year, offering those patients immunotherapy, targeted treatment, cell-based therapy and other cutting-edge treatments and diagnostic modalities, as well as access to clinical trials. Their provision of cancer care has continued unabated throughout the COVID-19 pandemic.
To learn more about RCCA, call (844) 346-7222 or visit RCCA.com.
For further information, contact:
Mary Campbell
marycampbell@regionalcancercare.org
(201) 579-9241
Black Americans with lung cancer are 18% less likely than white people to be diagnosed in the early stages of the disease, 23% less likely to receive surgery, and 21% less likely to survive 5 years after diagnosis, according to the American Lung Association.
Cancer can affect anyone from any background. However, some racial and ethnic groups have higher rates of certain kinds of cancer. Regional Cancer Care Associates
Infusion therapy is a treatment modality that administers medications intravenously. While most people associate infusions with cancer treatment, several different conditions can be managed and
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.
